Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 2 Study of Temsirolimus in Refractory and Recurrent Primary CNS Lymphoma

NCT00942747 is registered in ClinicalTrials.gov with Charite University, Berlin, Germany as lead sponsor.

NCT NCT00942747
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00942747 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 2 Study of Temsirolimus in Refractory and Recurrent Primary CNS Lymphoma
Lead sponsor
Charite University, Berlin, Germany
Phase
Phase 2
Overall status
Unknown status
Start date
July 31, 2009
Completion date
June 30, 2014
Enrollment
37 (estimated)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

recurrent or refractory primary cns lymphoma